Evaluation of a novel nicotine inhaler device: Part 2-effect on craving and smoking urges

Nicotine and Tobacco Research

Volumn 17, Issue 1, 2015, Pages 26-33

  Moyses, Chris ^a   Hearn, Alex ^a   Redfern, Andrew ^b  

^a Kind Consumer Limited   (United Kingdom)

^b Linear Clinical Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; NICOTINE GUM; NICOTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY THROAT; ERYTHEMA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPESTHESIA; INHALER; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NICOTINE REPLACEMENT THERAPY; OPEN STUDY; ORAL PARESTHESIA; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SMOKING; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOBACCO DEPENDENCE; WAKEFULNESS; WITHDRAWAL SYNDROME; XEROSTOMIA; ADOLESCENT; BLOOD; CLINICAL TRIAL; CRAVING; DRUG THERAPY; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; MIDDLE AGED; NEBULIZER; PROCEDURES; SMOKING CESSATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AREA UNDER CURVE; CRAVING; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NICOTINE; SMOKING; SMOKING CESSATION;

EID: 84922469414     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntu122     Document Type: Article

References (26)

1. World Health Organization. WHO report on the global tobacco epidemic, 2008: the MPOWER package. 2008. www.who.int/tobacco/mpower/mpower_report_full_2008.pdf.
2. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
3. West R, Owen L. Estimates of 52-week continuous abstinence rates following selected smoking cessation interventions in England. 2012. www.smokinginengland.info/reports/.
4. Schneider NG, Lunell E, Olmstead RE, Fagerström KO. Clinical pharmacokinetics of nasal nicotine delivery. a review and comparison to other nicotine systems. Clin Pharmacokinet. 1996;31:65-80.
5. Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet. 2001;40:661-684.
6. Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerström Test for Cigarette Dependence. Nicotine Tob Res. 2012;14:75-78.
7. Rose JE. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology. 2006;184:274-285.
8. Royal College of Physicians. Ending tobacco smoking in Britain: radical strategies for prevention and harm reduction in nicotine addiction. A report by the Tobacco Advisory Group of the Royal College of Physicians. 2008. www.rcplondon.ac.uk/sites/default/files/documents/ending-tobacco-smoking.pdf.
9. National Institute for Health and Care Excellence. NICE public health guidance 45. Tobacco: harm-reduction approaches to smoking. 2013. http://guidance.nice.org.uk/PH45.
10. Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L. Nicotine levels in electronic cigarettes. Nicotine Tob Res. 2013;15:158-166.
11. Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised crossover trial. Tob Control. 2010;19:98-103.
12. Dawkins L, Turner J, Hasna S, Soar K. The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. Addict Behav. 2012;37:970-973.
13. Djordjevic MV, Stellman SD, Zang E. Doses of nicotine and lung carcinogens delivered to cigarette smokers. J Natl Cancer Inst. 2000;92:106-111.
14. Shiffman S, West R, Gilbert D. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res. 2004;6:599-614.
15. Moyses C, Hearn A, Redfern A. Arterial pharmacokinetics of orally inhaled nicotine from a novel nicotine inhaler device (Unpublished). Presented at: 19th Annual International Meeting of the Society for Research on Nicotine and Tobacco; March 13-16, 2013; Boston, MA.
16. McNeil Products Limited. Nicorette® Inhalator SPC. 2010. www.medicines.org.uk/emc/medicine/1550/SPC/.
17. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3:7-16.
18. Lunell E, Molander L, Ekberg K, Wahren J. Site of nicotine absorption from a vapour inhaler-Comparison with cigarette smoking. Eur J Clin Pharmacol. 2000;55:737-741.
19. Hjalmarson A, Nilsson F, Sjöström L, Wiklund O. The nicotine inhaler in smoking cessation. Arch Intern Med. 1997;157:1721-1728.
20. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction. 1996;91:1293-1306.
21. Tønnesen P, Nørregaard J, Mikkelsen K, Jørgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA. 1993;269:1268-1271.
22. Caldwell B, Sumner W, Crane J. A systematic review of nicotine by inhalation: is there a role for the inhaled route? Nicotine Tob Res. 2012;14:1127-1139.
23. Rose JE. The role of upper airway stimulation in smoking. In: Pomerleau OF, Pomerleau CS, eds. Nicotine replacement: a critical evaluation. New York, NY: LISS; 1988:95-106.
24. Teague CE. Implications and activities arising from correlation of smoke pH with nicotine impact, other smoke qualities, and cigarette sales. 1973. http://tobaccodocuments.org/product_design/344.html.
25. Lunell E, Bergström M, Antoni G, Långström B, Nordberg A. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clin Pharmacol Ther. 1996;59:593-594.
26. Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther. 1997;62:453-463.